相关实验视频

Updated: Jul 14, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在可切除非小细胞肺癌中,使用 pembrolizumab 加上化疗的新辅助免疫化学疗法

Yulong Chen¹, Bo Yan², Ran Zhang³

¹Department of Lung Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.

|October 9, 2023

概括

新辅助免疫疗法与 pembrolizumab 和化疗是早期非小细胞肺癌的安全有效治疗方法. 达到病理完整反应或主要病理反应显著改善了生存结果.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
手术瘤学手术瘤学

背景情况:

新辅助免疫疗法是早期非小细胞肺癌 (NSCLC) 的关键治疗方法,旨在实现长期生存.
布罗利祖马布与化疗相结合正在研究作为可切除NSCLC的新辅助治疗方法.

研究的目的:

评估新辅助 pembrolizumab 加上化学疗法的安全性和有效性,用于切除性NSCLC的患者.
分析与治疗结果相关的病理反应率,无进展生存率 (PFS) 和总生存率 (OS).

主要方法:

对61名局部切除性NSCLC患者的回顾性分析,这些患者接受了新辅助 pembrolizumab 和化疗,随后进行手术.
评估病理完整反应 (pCR) 和重大病理反应 (MPR).
在总样本和子组中分析PFS和OS,包括淋巴结转移状态.

主要成果:

50.82%的患者实现了PCR,62.30%的患者实现了MPR.
pCR和MPR与改善的生存状况显著相关 (P<0.05).
手术后淋巴结转移是OS和PFS的显著负预后因素 (P<0.001).

结论:

新辅助性免疫化学疗法与 pembrolizumab 加上化学疗法在早期的 NSCLC 中是安全的和可以容忍的.
pCR和MPR是积极治疗反应和改善生存率的强有力的指标.
手术后的淋巴结转移是预测较差结果的关键因素.

关键词:

化学免疫疗法是一种化学免疫疗法.新辅助疗法是一种新辅助疗法.非小细胞肺癌是非小细胞肺癌.手术手术手术术术

更多相关视频

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...